Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Low T3 Syndrome
About this trial
This is an interventional prevention trial for Low T3 Syndrome focused on measuring congenital heart surgery, thyroid hormones
Eligibility Criteria
Inclusion Criteria:
- Patients between 0-2 years of age
- Aristotle score of 6 and above
- underwent cardiac surgery using cardiopulmonary bypass
Exclusion Criteria:
- birth weight less than 2 kg for neonates
- preoperative tachyarrhythmia or need for anti arrhythmic treatment
- clinical sepsis confirmed by culture
- preoperative renal insufficiency
- known thyroid and metabolic disorder
- any contraindication for oral T3 administration
Sites / Locations
- Pediatric Cardiac ICU National Cardiovascular Center Harapan Kita Jakarta
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Placebo Comparator
Experimental
Oral T3 low dose & placebo
Placebo
Oral T3 high dose
Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)